Trial
NCT03572478
Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
University of Chicago
Collaborators
Bristol-Myers Squibb; Clovis Oncology, Inc.
Condition
Prostate Cancer
Intervention
Rucaparib
Why stopped
The study was terminated due to lack of efficacy.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-03-09